Home » Stocks » SAVA

Cassava Sciences, Inc. (SAVA)

Stock Price: $77.63 USD -12.09 (-13.48%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $77.65 +0.02 (0.03%) Jun 22, 7:58 PM
Market Cap 3.11B
Revenue (ttm) n/a
Net Income (ttm) -8.71M
Shares Out 37.72M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE 94.34
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $77.63
Previous Close $89.72
Change ($) -12.09
Change (%) -13.48%
Day's Open 88.43
Day's Range 72.48 - 89.15
Day's Volume 6,482,255
52-Week Range 2.65 - 117.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.

14 hours ago - Zacks Investment Research

Cassava Sciences (SAVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company

16 hours ago - Zacks Investment Research

The stock price of ​Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimer's disease, has seen a massive 66% rise over the last twenty-one trading days, while it is ...

19 hours ago - Forbes

Investors applauded the company's update on its clinical programs.

1 day ago - The Motley Fool

Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease Selection of Premier Research as CRO Marks Significant Milestone...

1 day ago - GlobeNewsWire

Cassava Sciences Inc (NASDAQ:SAVA) shares are trading higher by 11.2% at $88.50 after the company highlighted clinical development progress and provided guidance on upcoming data releases for simufilam,...

1 day ago - Benzinga

Cassava Sciences Inc (NASDAQ: SAVA) has announced a mid-year update highlighting clinical development progress and providing guidance on upcoming data releases for simufilam and SavaDx.  Simufilam is Ca...

1 day ago - Benzinga

AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced a mid-year update that highlights clinical...

1 day ago - GlobeNewsWire

Cassava Sciences, Inc. (SAVA) closed at $79.65 in the latest trading session, marking a +1.34% move from the prior day.

4 days ago - Zacks Investment Research

AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited to...

5 days ago - GlobeNewsWire

New approaches to treating Alzheimer's could mean even bigger gains in the future.

Other stocks mentioned: BIIB
6 days ago - The Motley Fool

- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals –

1 week ago - GlobeNewsWire

Data doesn't lie. These companies have the potential to quickly steal the spotlight.

Other stocks mentioned: ANVS
1 week ago - The Motley Fool

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in thei...

Other stocks mentioned: ANVS, LLY
2 weeks ago - Zacks Investment Research

Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval.

2 weeks ago - The Motley Fool

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

4 weeks ago - Zacks Investment Research

- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time -

4 weeks ago - GlobeNewsWire

Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jer...

Other stocks mentioned: CLBS
1 month ago - Benzinga

- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Pha...

1 month ago - GlobeNewsWire

It signals a big push toward curing a neurological disease with a massive market.

Other stocks mentioned: DNLI, LLY, MRNA, SNY
1 month ago - The Motley Fool

- Randomized, Controlled Study is Designed to Evaluate Cognition  in Patients Who Continue Versus Discontinue Simufilam Over Six Months –

1 month ago - GlobeNewsWire

Fireside Chat on Wednesday, April 28th at 2:30PM Eastern Fireside Chat on Wednesday, April 28th at 2:30PM Eastern

1 month ago - GlobeNewsWire

AUSTIN, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited t...

1 month ago - GlobeNewsWire

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Other stocks mentioned: AVXL, AXSM, BIIB, JAZZ
2 months ago - Zacks Investment Research

- 9 Month Interim Analysis of Open-label Study to be Presented at  a Major Scientific Conference in July 2021 as an Oral Presentation -

2 months ago - GlobeNewsWire

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $34.85, marking a -0.68% move from the previous day.

2 months ago - Zacks Investment Research

These high-flying stocks may soon reverse course.

Other stocks mentioned: AAL, AMC, GME, ZOM
2 months ago - The Motley Fool

Being able to scout for future growth potential is a crucial pillar of investing success.

Other stocks mentioned: AAL, BLNK
2 months ago - The Motley Fool

These stocks have been unstoppable since late December -- but will they stay that way?

Other stocks mentioned: BNGO, GME, OCGN, ZOM
2 months ago - The Motley Fool

Is (SAVA) Outperforming Other Medical Stocks This Year?

2 months ago - Zacks Investment Research

AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the ...

2 months ago - GlobeNewsWire

A potential new treatment for Alzheimer's disease could be worth billions.

3 months ago - The Motley Fool

If nothing happens – and that's the hope – this article will be nothing but a good laugh. However, astute investors should at least know about these stocks that could crash.

Other stocks mentioned: BGI, EXPR, KOSS, MARA, NVAX, SINO
3 months ago - InvestorPlace

The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimers, has seen a 7% rise over the last ten trading days, while it is up 1% over the last five t...

3 months ago - Forbes

Here's why these attention-grabbing stocks could be toxic to your portfolio.

Other stocks mentioned: OCGN, RUBY
3 months ago - The Motley Fool

An analyst expects shares to more than double over the next 12 months.

3 months ago - The Motley Fool

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Other stocks mentioned: UBER
3 months ago - Benzinga

Though the U.S. economy is far from pre-pandemic levels, it has shown solid improvement. Meanwhile, the stock market has strongly bounced back and reached new milestones.

Other stocks mentioned: DEN, MARA, RIOT, SI
3 months ago - Zacks Investment Research

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

3 months ago - Zacks Investment Research

AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today announced it ...

3 months ago - GlobeNewsWire

Is (SAVA) Outperforming Other Medical Stocks This Year?

3 months ago - Zacks Investment Research

Promising results for the company's lead Alzheimer's drug have made Cassava one of 2021's most exciting stocks.

3 months ago - The Motley Fool

AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, has been invited to...

3 months ago - GlobeNewsWire

Its promising potential treatment for Alzheimer's disease is going to enter phase 3 trials later this year.

3 months ago - The Motley Fool

SAVA stock has plenty of long-term potential after the company posted clinical results from its Alzheimer's disease study. The post Why Cassava Sciences Has Tremendous Upside Potential appeared first on...

3 months ago - InvestorPlace

Cassava Sciences will likely be a winner in the fight against Alzheimer's. If successful, SAVA stock is worth significantly more.

3 months ago - InvestorPlace

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $52.37, moving -1.23% from the previous trading session.

3 months ago - Zacks Investment Research

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

3 months ago - Zacks Investment Research

AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, has been invited to ...

3 months ago - GlobeNewsWire

About SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, T... [Read more...]

Industry
Biotechnology
Founded
1998
CEO
Remi Barbier
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
SAVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is 77.80, which is an increase of 0.22% from the latest price.

Price Target
$77.80
(0.22% upside)
Analyst Consensus: Buy